source
- FDA grants accelerated approval to Tudriqev viral therapy for PD-1-refractory advanced melanomaThe U.S. Food and Drug Administration has granted accelerated approval to Tudriqev (vusolimogene oderparepvec-wtpg), a genetically engineered oncolytic viral therapy for patients with advanced, tre…
- Attovia Therapeutics raises $289 million in IPO, adding third I&I drug to market debutAttovia Therapeutics, a biotech focused on immunology and inflammation, completed an initial public offering that raised about $289 million. The funds will support the development of three I&I dru…